Very Short Dual Antiplatelet Therapy after Drug-eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2 Trial.
暂无分享,去创建一个
H. Okayama | K. Tanabe | Takeshi Kimura | Y. Ikari | Y. Morino | T. Morimoto | H. Shiomi | K. Takagi | K. Nakao | K. Kozuma | Masahiro Natsuaki | Hirotoshi Watanabe | K. Ando | K. Kadota | Y. Furukawa | S. Suwa | H. Sakamoto | Y. Nakagawa | Yoshiki Hata | I. Takamisawa | T. Tada | M. Abe | K. Hibi | N. Suematsu | T. Noda | M. Doi | K. Hanaoka | T. Domei | T. Toyota | M. Ohya | M. Nanasato | Masahiro Yagi | T. Yokomatsu | Yoshitane Seino | K. Kawai | Takafumi Yokomatsu
[1] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[2] M. Price,et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.
[3] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[4] F. Eberli,et al. Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.
[5] P. Kolh,et al. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.
[6] A. Jaffe,et al. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .